A 12-month trial across 31 Australian general practices found that a nurse-led program combining personalized lifestyle counseling with a smartphone app modestly improved estimated dementia risk scores in middle-aged adults. The study, published in The Lancet Regional Health - Western Pacific, was known as HAPPI MIND and enrolled adults aged 45 to 65 who had at least two modifiable dementia risk factors.
Participants in the intervention arm attended six nurse-led sessions, five in the first year and one at 24 months, using behavior-change techniques to address vascular, lifestyle and psychosocial risk factors. They used the HAPPI MIND app to track goals and access education. Control participants received a brief baseline intervention, a risk report and an educational booklet, and otherwise continued usual care. The primary outcome was the change in the ANU-ADRI score, a questionnaire-based index in which lower scores indicate a more favorable risk profile.
At 12 months, 56% of intervention participants had improved scores compared with 44% of controls, an adjusted between-group difference of 1.6 points. Most of the gain came from protective factors, with greater improvements in physical activity, fish intake and BMI status. Risk-factor scores did not differ between groups, and the study found no significant differences in cognition, quality of life, cardiovascular risk or psychosocial measures.
The researchers say the results suggest that practice nurses could deliver tailored prevention within routine primary care, a setting that already handles chronic disease management. An exploratory analysis hinted at larger benefits for people with low socioeconomic status or high baseline dementia risk, but the researchers note these findings need confirmation in larger studies because the low-socioeconomic subgroup was small. The authors also flag open-label design, self-reported outcomes, baseline imbalances and variable app use as possible sources of bias, and state that the independent effect of the app remains unclear. Longer follow-up, planned to 36 months, is needed to judge sustainability, generalisability, cost-effectiveness and any effect on cognition or dementia incidence.